European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 ...

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...